Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions not accepted — page 4

The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

Submissions

147 documents · page 4 of 5

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-SS-31-MONOGR/015Draft monograph: SS-31 (elamipretide)Dr Rukayat Zaleski-Mbeki industryThe document should not describe uses outside the approved indication
DRAFT-SS-31-MONOGR/001Draft monograph: SS-31 (elamipretide)Dr Theodora TrelawneyThe document set should be published in translation
DRAFT-SURVODUTIDE-/004Draft monograph: SurvodutideDr Liesbeth AchterbergThe monograph should state what the compound costs
DRAFT-SURVODUTIDE-/006Draft monograph: SurvodutideDr Hyacinth Oyelaran-SteenThe document set should be published in translation
DRAFT-SURVODUTIDE-/014Draft monograph: SurvodutideValentin Tollemache industryThe document should not describe uses outside the approved indication
DRAFT-TESAMORELIN-/005Draft monograph: TesamorelinDr Bertrand Steenkamp-FerreiraThe document should state what a reader ought to do
DRAFT-TESAMORELIN-/012Draft monograph: TesamorelinDr Georgiana Mountstephen industryThe document should not describe uses outside the approved indication
DRAFT-TESAMORELIN-/014Draft monograph: TesamorelinRosalind PetrossianThe document set should be published in translation
DRAFT-THYMALIN-MON/009Draft monograph: ThymalinDr Ludmila TollemacheThe document should state what a reader ought to do
DRAFT-THYMOSIN-ALP/011Draft monograph: Thymosin alpha-1Ivo MountstephenThe document set should be published in translation
DRAFT-THYMOSIN-ALP/012Draft monograph: Thymosin alpha-1Dr Wilhelmina QuaresmaThe document should state what a reader ought to do
DRAFT-THYMOSIN-BET/001Draft monograph: Thymosin beta-4Dr Vittoria YlönenThe document set should be published in translation
DRAFT-PEPTIDE-CONT/006Draft standard CEI-MS-03: Determination of peptide content and its…Dr Frideswide HazelriggThe standard should state a pass limit
DRAFT-PEPTIDE-CONT/011Draft standard CEI-MS-03: Determination of peptide content and its…Dr Vasilisa ImmelmannThe document should state what a reader ought to do
DRAFT-STERILITY-US/001Draft standard CEI-MS-06: Sterility testing of peptide preparations…Dr Ursina Ellsworth-VanceThe document should state what a reader ought to do
DRAFT-STERILITY-US/006Draft standard CEI-MS-06: Sterility testing of peptide preparations…Dr Jacinta Grünbaum-SowandeThe document set should be published in translation
DRAFT-PARTICULATE-/001Draft standard CEI-MS-07: Sub-visible particulate matter in…Dr Theodora XimenesThe standard should state a pass limit
DRAFT-PARTICULATE-/013Draft standard CEI-MS-07: Sub-visible particulate matter in…Dr Wolfram Kaltenbach-MensahThe document set should be published in translation
DRAFT-RELATED-SUBS/001Draft standard CEI-MS-08: Related-substances profiling and the…Dr Quentin EnthovenThe document set should be published in translation
DRAFT-RELATED-SUBS/008Draft standard CEI-MS-08: Related-substances profiling and the…Dr Séverine Oduya-Kaltenbrunner industryThe document should not describe uses outside the approved indication
DRAFT-COUNTER-ION-/001Draft standard CEI-MS-10: Identification and quantification of…Dr Quentin EnthovenThe document set should be published in translation
DRAFT-AGGREGATES-S/006Draft standard CEI-MS-11: Determination of aggregate content by…Dr Quintus RautavaaraThe document set should be published in translation
DRAFT-RESIDUAL-SOL/001Draft standard CEI-MS-12: Residual solvent determination by static…Xenia Nyquist-ObioraThe standard should state a pass limit
DRAFT-RESIDUAL-SOL/009Draft standard CEI-MS-12: Residual solvent determination by static…Dr Rukayat Zaleski-MbekiThe standard should require documented operator competence
DRAFT-STABILITY-IN/003Draft standard CEI-MS-13: Development and validation of a…Xenia Nyquist-ObioraThe document should state what a reader ought to do
DRAFT-STABILITY-IN/008Draft standard CEI-MS-13: Development and validation of a…Leonhard AchterbergThe document set should be published in translation
DRAFT-STABILITY-IN/012Draft standard CEI-MS-13: Development and validation of a…Dr Evander Whitmarsh-ObiThe standard should state a pass limit
DRAFT-STABILITY-IN/005Draft standard CEI-MS-13: Development and validation of a…Dr Stellan Cholmondeley-AdeThe standard should require documented operator competence
DRAFT-STABILITY-IN/001Draft standard CEI-MS-13: Development and validation of a…Vittoria Quintanilha industryThe document should not describe uses outside the approved indication
DRAFT-THIRD-PARTY-/010Draft standard CEI-MS-15: Protocol for independent third-party…Dr Oisín RautavaaraThe standard should require documented operator competence

page 4 of 5

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.